232 related articles for article (PubMed ID: 21615749)
21. Platelet transfusion refractoriness responding preferentially to single donor aphaeresis platelets compatible for both ABO and HLA.
McVey M; Cserti-Gazdewich CM
Transfus Med; 2010 Oct; 20(5):346-53. PubMed ID: 20492602
[TBL] [Abstract][Full Text] [Related]
22. Platelet alloimmunization after long-term red cell transfusion in transfusion-dependent thalassemia patients.
Lo SC; Chang JS; Lin SW; Lin DT
Transfusion; 2005 May; 45(5):761-5. PubMed ID: 15847666
[TBL] [Abstract][Full Text] [Related]
23. Analysis of platelet-reactive alloantibodies and evaluation of cross-match-compatible platelets for the management of patients with transfusion refractoriness.
Wang J; Xia W; Deng J; Xu X; Shao Y; Ding H; Chen Y; Liu J; Chen D; Ye X; Santoso S
Transfus Med; 2018 Feb; 28(1):40-46. PubMed ID: 28516675
[TBL] [Abstract][Full Text] [Related]
24. In-Depth Analysis of Anti-HLA Antibodies Using C1q Assay.
Zielińska H; Zieliński M; Dębska-Zielkowska J; Dukat-Mazurek A; Moszkowska G; Lewandowska D; Dębska-Ślizień A; Trzonkowski P
Transplant Proc; 2022 May; 54(4):934-939. PubMed ID: 35534279
[TBL] [Abstract][Full Text] [Related]
25. Utilization of cross-matched or HLA-matched platelets for patients refractory to platelet transfusion.
Rioux-Massé B; Cohn C; Lindgren B; Pulkrabek S; McCullough J
Transfusion; 2014 Dec; 54(12):3080-7. PubMed ID: 24916382
[TBL] [Abstract][Full Text] [Related]
26. A comparison of two robotic platforms to screen plateletpheresis donors for HLA antibodies as part of a transfusion-related acute lung injury mitigation strategy.
Vassallo RR; Hsu S; Einarson M; Barone J; Brodsky J; Moroff G
Transfusion; 2010 Aug; 50(8):1766-77. PubMed ID: 20345569
[TBL] [Abstract][Full Text] [Related]
27. Validation of HLAMatchmaker algorithm in identifying acceptable HLA mismatches for thrombocytopenic patients refractory to platelet transfusions.
Brooks EG; MacPherson BR; Fung MK
Transfusion; 2008 Oct; 48(10):2159-66. PubMed ID: 18631168
[TBL] [Abstract][Full Text] [Related]
28. Getting on target: Development of the novel, prozone-resistant, dual antibody rapid test (DART) for the LABScreen single antigen bead (SAB) assay.
Greenshields A; Bray RA; Gebel HM; Liwski RS
Hum Immunol; 2019 Jul; 80(7):468-477. PubMed ID: 31040048
[TBL] [Abstract][Full Text] [Related]
29. [An evaluation of platelet transfusion response using HLA crossmatch-compatible donors in patients with platelet refractoriness].
Hyun J; Lim YM; Park KD; Han BY; Kim YH; Han KS; Park MH
Korean J Lab Med; 2009 Oct; 29(5):481-9. PubMed ID: 19893359
[TBL] [Abstract][Full Text] [Related]
30. The complement-activating capacity of maternal IgG antibodies to blood group A in paired mother/child serum samples.
Hari Y; von Allmen EC; Boss GM; Naiem A; Gittermann M; Nydegger UE
Vox Sang; 1998; 74(2):95-100. PubMed ID: 9501407
[TBL] [Abstract][Full Text] [Related]
31. Methods for the selection of platelet products for alloimmune-refractory patients.
Kopko PM; Warner P; Kresie L; Pancoska C
Transfusion; 2015 Feb; 55(2):235-44. PubMed ID: 25393955
[TBL] [Abstract][Full Text] [Related]
32. Complement-fixing donor-specific antibodies identified by a novel C1q assay are associated with allograft loss.
Sutherland SM; Chen G; Sequeira FA; Lou CD; Alexander SR; Tyan DB
Pediatr Transplant; 2012 Feb; 16(1):12-7. PubMed ID: 22093755
[TBL] [Abstract][Full Text] [Related]
33. [Establish a Graded Method to Avoid HLA Class I Antibodies Corresponding Antigen and Combining HLAMatchmaker Application in Improving the CCI Value after Platelet Transfusion for Patients with IPTR].
Gao SQ; Xu YP; Luo CR; Li DC; Pen L; Liu T; Zou QC
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Feb; 32(1):242-249. PubMed ID: 38387929
[TBL] [Abstract][Full Text] [Related]
34. Therapeutic Human IgG Preparations Contain Mixture of HLA Antibodies to Native HLA Antigens and Cryptic Epitopes With Little Clinical Significance.
Mangiola M; Marrari M; Ensor C; Spycher MO; Berger M; Zeevi A
Transplantation; 2018 Dec; 102(12):2126-2132. PubMed ID: 29877923
[TBL] [Abstract][Full Text] [Related]
35. Prevalence and specificity of immunoglobulin G and immunoglobulin A non-complement-binding anti-HLA alloantibodies in retransplant candidates.
Arnold ML; Dechant M; Doxiadis II; Spriewald BM
Tissue Antigens; 2008 Jul; 72(1):60-6. PubMed ID: 18588575
[TBL] [Abstract][Full Text] [Related]
36. [Platelet allo-antibodies identification strategies for preventing and managing platelet refractoriness].
Basire A; Picard C
Transfus Clin Biol; 2014 Nov; 21(4-5):193-206. PubMed ID: 25277423
[TBL] [Abstract][Full Text] [Related]
37. Correlation of Circulating Complement-Fixing Donor-Specific Antibodies Identified by the C1q Assay and Presence of C4d in Endomyocardial Biopsy Specimens.
Frank R; Lal P; Kearns J; Molina MR; Wald JW; Goldberg LR; Kamoun M
Am J Clin Pathol; 2016 Jan; 145(1):62-8. PubMed ID: 26712872
[TBL] [Abstract][Full Text] [Related]
38. A comparison of volume-reduced versus standard HLA/HPA-matched apheresis platelets in alloimmunized adult patients.
Honohan A; Tomson B; van der Bom J; de Vries R; Brand A
Transfusion; 2012 Apr; 52(4):742-51. PubMed ID: 21981629
[TBL] [Abstract][Full Text] [Related]
39. Genetically engineered blood pharming: generation of HLA-universal platelets derived from CD34+ progenitor cells.
Figueiredo C; Blaszczyk R
J Stem Cells; 2014; 9(3):149-61. PubMed ID: 25157449
[TBL] [Abstract][Full Text] [Related]
40. [Platelet alloimmunization in patients with oncologic blood disorders treated with multiple transfusions: prospective study in adults and children].
Pereira J; Bronfman L; Bertín P; Marzouka E; Hidalgo P; Amaya S; Mezzano D
Rev Med Chil; 1997 Nov; 125(11):1305-12. PubMed ID: 9609051
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
